Pharmacological treatment of acute lymphoblastic leukaemia in paediatric patients
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Al-Kasem, Abdullah | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Megyeri, Attila | |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2022-08-17T08:47:33Z | |
| dc.date.available | 2022-08-17T08:47:33Z | |
| dc.date.created | 2022-04-22 | |
| dc.description.abstract | Vincristine is the most optimal and the drug of choice in the treatment regimen of ALL in pediatric patients. Both Dexamethason and Prednisolone are used in the treatment of ALL, where one of them has a high therapeutic index while the other one is safer to use. A four-drug regimen is needed in case of high-risk ALL. | hu_HU |
| dc.description.corrector | hbk | |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 34 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/336535 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Paediatric ALL | hu_HU |
| dc.subject | ALL treatment | hu_HU |
| dc.subject | Vincristine | hu_HU |
| dc.subject | corticosteroids-induced osteonecrosis | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Pharmacological treatment of acute lymphoblastic leukaemia in paediatric patients | hu_HU |